|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
152,570,000 |
Market
Cap: |
334.13(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.06 - $2.55 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 21.1 |
Insider 3/6 Months : 21.7 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. info@atai.life
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
12,635,718 |
12,635,718 |
12,695,718 |
Total Buy Value |
$0 |
$25,275,008 |
$25,275,008 |
$25,356,096 |
Total People Bought |
0 |
1 |
1 |
2 |
Total Buy Transactions |
0 |
2 |
2 |
4 |
Total Shares Sold |
0 |
182,250 |
182,250 |
458,404 |
Total Sell Value |
$0 |
$246,037 |
$246,037 |
$767,514 |
Total People Sold |
0 |
5 |
5 |
6 |
Total Sell Transactions |
0 |
5 |
5 |
9 |
End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Angermayer Christian |
|
|
2025-03-24 |
4 |
B |
$1.40 |
$2,520,000 |
I/I |
1,800,000 |
42,369,415 |
0.01 |
40% |
|
Short Glenn Frank |
Chief Scientific Officer |
|
2025-03-21 |
4 |
S |
$1.35 |
$17,767 |
D/D |
(13,161) |
42,333 |
|
-52% |
|
Rao Srinivas |
See Remarks |
|
2025-03-21 |
4 |
S |
$1.35 |
$101,814 |
D/D |
(75,418) |
212,942 |
|
-52% |
|
Kirpekar Sahil |
Chief Business Officer |
|
2025-03-21 |
4 |
S |
$1.35 |
$65,560 |
D/D |
(48,563) |
115,636 |
|
-52% |
|
Craig Kevin James |
Chief Medical Officer |
|
2025-03-21 |
4 |
S |
$1.35 |
$15,610 |
D/D |
(11,563) |
8,437 |
|
-52% |
|
Johnson Anne Nagengast |
Chief Financial Officer |
|
2025-03-21 |
4 |
S |
$1.35 |
$45,286 |
D/D |
(33,545) |
140,045 |
|
-52% |
|
Rao Srinivas |
See Remarks |
|
2025-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
175,000 |
288,360 |
|
- |
|
Johnson Anne Nagengast |
Chief Financial Officer |
|
2025-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
100,000 |
173,590 |
|
- |
|
Kirpekar Sahil |
Chief Business Officer |
|
2025-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
100,000 |
164,199 |
|
- |
|
Short Glenn Frank |
Chief Scientific Officer |
|
2025-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,500 |
55,494 |
|
- |
|
Craig Kevin James |
Chief Medical Officer |
|
2025-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
Angermayer Christian |
|
|
2025-02-14 |
4 |
B |
$2.10 |
$22,755,008 |
I/I |
10,835,718 |
40,555,215 |
0.01 |
-2% |
|
Short Glenn Frank |
Chief Scientific Officer |
|
2025-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,994 |
|
-11% |
|
Brand Florian |
See Remarks |
|
2024-05-16 |
4 |
S |
$1.92 |
$290,502 |
D/D |
(151,303) |
328,697 |
|
36% |
|
Johnson Anne Nagengast |
Chief Financial Officer |
|
2024-04-02 |
4 |
S |
$1.85 |
$50,709 |
D/D |
(27,410) |
73,590 |
|
35% |
|
Rao Srinivas |
See Remarks |
|
2024-04-02 |
4 |
S |
$1.85 |
$114,034 |
D/D |
(61,640) |
113,360 |
|
35% |
|
Kirpekar Sahil |
Chief Business Officer |
|
2024-04-02 |
4 |
S |
$1.85 |
$66,232 |
D/D |
(35,801) |
64,199 |
|
35% |
|
Johnson Anne Nagengast |
Chief Financial Officer |
|
2024-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
100,000 |
101,000 |
|
- |
|
Rao Srinivas |
See Remarks |
|
2024-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
175,000 |
175,000 |
|
- |
|
Brand Florian |
See Remarks |
|
2024-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
350,000 |
480,000 |
|
- |
|
Kirpekar Sahil |
Chief Business Officer |
|
2024-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
|
- |
|
Brand Florian |
See Remarks |
|
2023-11-16 |
4 |
B |
$1.16 |
$23,120 |
D/D |
20,000 |
130,000 |
0.01 |
77% |
|
Brand Florian |
See Remarks |
|
2023-09-13 |
4 |
B |
$1.45 |
$57,968 |
D/D |
40,000 |
110,000 |
0.01 |
30% |
|
Brand Florian |
See Remarks |
|
2023-03-29 |
4 |
B |
$1.48 |
$103,558 |
D/D |
70,000 |
70,000 |
2.74 |
10% |
|
Angermayer Christian |
10% Owner |
|
2023-03-29 |
4 |
B |
$1.32 |
$1,600,443 |
I/I |
1,214,297 |
32,086,697 |
1.5 |
10% |
|
54 Records found
|
|
Page 1 of 3 |
|
|